Despite fewer people smoking and effective therapies for hypertension and high cholesterol, cardiovascular disease remains the number one cause of death worldwide¹.

This epidemic is driven by demographic factors like an aging population, decreasing mortality from other factors (such as infectious disease), and rising rates of obesity—which can drive the progression of metabolic diseases, such as Type 2 diabetes, and lead to the “metabolic syndrome,” a constellation of risk factors that increase an individual’s risk for heart disease and other health problems¹.

For more than 50 years, we have led the way in redefining the management of cardiovascular risk by bringing much-needed treatments to patients².

In cardiovascular therapy area, our endeavours have been to disseminate recent updates in Atrial fibrillation (AF) and venous thromboembolism (VTE) to healthcare professionals, and create awareness on the nuances in the management of stroke prevention in AF and treatment of VTE. AF and VTE are common conditions among older adults. Over their lifetime, approximately 1 in 4 individuals will experience AF,while 1 in 8 will develop VTE³. Our initiatives helped address practical challenges faced by a physician while initiating an oral anticoagulant in patients with AF and VTE.

Our early discovery efforts focus on emerging areas of cardiovascular research such as control of eating disorders, Type 2 diabetes/ muscle uptake of glucose and non-alcoholic fatty liver disease/non-alcoholic steatohepatitis².